Focus Antitrust - 11 June 2020
min readIn The News
CMA obtains director disqualification undertakings from pharmaceutical company director
The CMA has obtained director disqualification undertakings from a director of pharmaceutical companies involved in the CMA’s investigations into agreements relating to the supply of nortriptyline and fludrocortisone. Click here.
Advocate General advises upholding Lundbeck pay for delay decision
An Advocate General’s opinion has proposed that the ECJ should uphold the European Commission’s decision in the Lundbeck pay for delay case. Click here.
European Commission sends supplementary Statement of Objections to Teva on suspected 'pay-for-delay' pharma agreement
The European Commission has sent a supplementary Statement of Objections to Teva Pharmaceutical Industries Ltd. and Cephalon Inc., now a subsidiary of Teva. It follows the Commission's original Statement of Objections, in which the Commission had reached the preliminary conclusion that the patent settlement agreement between Cephalon and Teva concerning the sleeping disorder medicine modafinil may have delayed the entry of a cheaper generic medicine, in breach of Article 101. Click here.
EU
Mergers
- The European Commission has approved the proposed acquisition of Bayer AGs animal health division by Elanco Animal Health Inc. The decision is conditional on the divestment of otitis products and several types of parasiticides in the European Economic Area, the UK and globally. Click here.
UK
CMA
- The CMA has published an updated case timetable following the remittal by the Court of Appeal of its investigation into alleged excessive and unfair prices for phenytoin sodium capsules. Click here.
